Enzyvant today announced the U.S. Food and Drug Administration (FDA) approval of RETHYMIC® (allogeneic processed thymus tissue-agdc), a one-time regenerative tissue-based therapy for immune reconstitution in pediatric patients with congenital athymia.
The prevalent diagnosed cases of Pediatric Congenital athymia (PCA) in the USA ranges between 1.15 to 1.95 cases per 100,000 with an equal proportion of male and female. Patients who were diagnosed with congenital athymia more than 1 month after birth was diagnosed at a median age of 3 months, the median age at death was 24 months.
Comprehensive insight on patient segmentation based on age, sex, diagnosed population; Incidence/ Prevalence d by mutations (FOXN1, PAX1, TBX1, CHD7, FOXI3, TBX2), Clinical Manifestations (Infections; pulmonary, Skin, Gastrointestinal, Genitourinary, CNS, Ear, Nose, Eye & Throat), Autologous GVHD, Autoimmunity; hypothyroidism, autoimmune thyroiditis, and Coombs-positive hemolytic anemia has been provided into the epidemiology and treatment section of Pediatric Congenital Athymia in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,